Update shared on07 Aug 2025
Fair value Increased 12%Despite a further deterioration in consensus revenue growth forecasts, Cryoport’s valuation has expanded as reflected in a higher future P/E ratio, resulting in a notable increase in the consensus analyst price target from $10.81 to $12.11.
What's in the News
- Cryoport reiterated its full-year 2025 revenue guidance, expecting total revenue from continuing operations of $165 million to $172 million, representing 5% to 10% year-over-year growth.
- Cryoport launched next-generation MVE Biological Solutions vapor shippers (SC 4/2V and SC 4/3V), featuring extended hold times (up to 19 and 26 days, respectively), improved impact resistance, a new lid locking tab, and Vapor Shield Technology to enhance safety and reliability in transporting sensitive biological materials.
Valuation Changes
Summary of Valuation Changes for Cryoport
- The Consensus Analyst Price Target has significantly risen from $10.81 to $12.11.
- The Consensus Revenue Growth forecasts for Cryoport has fallen from -4.3% per annum to -4.7% per annum.
- The Future P/E for Cryoport has risen from 25.45x to 27.40x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.